Report
Dawid Górzyński

Celon Pharma - Disappointing 1Q19 results (slightly negative)

Research prepared by PKO BP Securities
Underlying
Celon Pharma SA

Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.

Provider
PKO Bank Polski
PKO Bank Polski

Analysts
Dawid Górzyński

Other Reports on these Companies
Other Reports from PKO Bank Polski

ResearchPool Subscriptions

Get the most out of your insights

Get in touch